These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 24423299)

  • 21. Soluble endoglin and other circulating antiangiogenic factors in preeclampsia.
    Levine RJ; Lam C; Qian C; Yu KF; Maynard SE; Sachs BP; Sibai BM; Epstein FH; Romero R; Thadhani R; Karumanchi SA;
    N Engl J Med; 2006 Sep; 355(10):992-1005. PubMed ID: 16957146
    [TBL] [Abstract][Full Text] [Related]  

  • 22. In vivo uteroplacental release of placental growth factor and soluble Fms-like tyrosine kinase-1 in normal and preeclamptic pregnancies.
    Holme AM; Roland MC; Henriksen T; Michelsen TM
    Am J Obstet Gynecol; 2016 Dec; 215(6):782.e1-782.e9. PubMed ID: 27503620
    [TBL] [Abstract][Full Text] [Related]  

  • 23. First-trimester serum levels of soluble endoglin and soluble fms-like tyrosine kinase-1 as first-trimester markers for late-onset preeclampsia.
    Baumann MU; Bersinger NA; Mohaupt MG; Raio L; Gerber S; Surbek DV
    Am J Obstet Gynecol; 2008 Sep; 199(3):266.e1-6. PubMed ID: 18771978
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A longitudinal study of plasma levels of soluble fms-like tyrosine kinase 1 (sFlt1), placental growth factor (PlGF), sFlt1: PlGF ratio and vascular endothelial growth factor (VEGF-A) in normal pregnancy.
    Palm M; Basu S; Larsson A; Wernroth L; Åkerud H; Axelsson O
    Acta Obstet Gynecol Scand; 2011 Nov; 90(11):1244-51. PubMed ID: 21568945
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Soluble fms-Like tyrosine kinase 1 (sFlt1), endoglin and placental growth factor (PlGF) in preeclampsia among high risk pregnancies.
    Powers RW; Jeyabalan A; Clifton RG; Van Dorsten P; Hauth JC; Klebanoff MA; Lindheimer MD; Sibai B; Landon M; Miodovnik M;
    PLoS One; 2010 Oct; 5(10):e13263. PubMed ID: 20948996
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Biomarker Immunoassays in the Diagnosis of Preeclampsia: Calculating the sFlt1/PlGF Ratio Using the Cobas
    Black C; da Silva Costa F
    Methods Mol Biol; 2018; 1710():9-26. PubMed ID: 29196991
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A longitudinal analysis of angiotensin II type 1 receptor antibody and angiogenic markers in pregnancy.
    Aggarwal S; Sunderland N; Thornton C; Xu B; Hennessy A; Makris A
    Am J Obstet Gynecol; 2017 Feb; 216(2):170.e1-170.e8. PubMed ID: 27793555
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Dysregulation of circulating autoantibodies against VEGF-A, VEGFR-1 and PlGF in preeclampsia - A role in placental and vascular health?
    Moe K; Heidecke H; Dechend R; Staff AC
    Pregnancy Hypertens; 2017 Oct; 10():83-89. PubMed ID: 29153696
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Angiogenic biomarkers for prediction of early preeclampsia onset in high-risk women.
    Moore Simas TA; Crawford SL; Bathgate S; Yan J; Robidoux L; Moore M; Maynard SE
    J Matern Fetal Neonatal Med; 2014 Jul; 27(10):1038-48. PubMed ID: 24066977
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Maternal serum-soluble vascular endothelial growth factor receptor-1 in early pregnancy ending in preeclampsia or intrauterine growth retardation.
    Wathén KA; Tuutti E; Stenman UH; Alfthan H; Halmesmäki E; Finne P; Ylikorkala O; Vuorela P
    J Clin Endocrinol Metab; 2006 Jan; 91(1):180-4. PubMed ID: 16263826
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Endometrial VEGF induces placental sFLT1 and leads to pregnancy complications.
    Fan X; Rai A; Kambham N; Sung JF; Singh N; Petitt M; Dhal S; Agrawal R; Sutton RE; Druzin ML; Gambhir SS; Ambati BK; Cross JC; Nayak NR
    J Clin Invest; 2014 Nov; 124(11):4941-52. PubMed ID: 25329693
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Accuracy of circulating placental growth factor, vascular endothelial growth factor, soluble fms-like tyrosine kinase 1 and soluble endoglin in the prediction of pre-eclampsia: a systematic review and meta-analysis.
    Kleinrouweler CE; Wiegerinck MM; Ris-Stalpers C; Bossuyt PM; van der Post JA; von Dadelszen P; Mol BW; Pajkrt E;
    BJOG; 2012 Jun; 119(7):778-87. PubMed ID: 22433027
    [TBL] [Abstract][Full Text] [Related]  

  • 33. MIF Increases sFLT1 Expression in Early Uncomplicated Pregnancy and Preeclampsia.
    Yong Q; Dijkstra KL; van der Keur C; Bruijn JA; Eikmans M; Baelde HJ
    Int J Mol Sci; 2023 Jun; 24(12):. PubMed ID: 37373198
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Relation between circulating angiotensin II type 1 receptor agonistic autoantibodies and soluble fms-like tyrosine kinase 1 in the pathogenesis of preeclampsia.
    Stepan H; Faber R; Wessel N; Wallukat G; Schultheiss HP; Walther T
    J Clin Endocrinol Metab; 2006 Jun; 91(6):2424-7. PubMed ID: 16569734
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Smooth Muscle Mineralocorticoid Receptor Promotes Hypertension After Preeclampsia.
    Biwer LA; Lu Q; Ibarrola J; Stepanian A; Man JJ; Carvajal BV; Camarda ND; Zsengeller Z; Skurnik G; Seely EW; Karumanchi SA; Jaffe IZ
    Circ Res; 2023 Mar; 132(6):674-689. PubMed ID: 36815487
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A simple detection method for the serum sFLT1 protein in preeclampsia.
    Shibuya M; Matsui H; Sasagawa T; Nagamatsu T
    Sci Rep; 2021 Oct; 11(1):20613. PubMed ID: 34663835
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Angiogenesis in gestational vascular complications.
    Yagel S
    Thromb Res; 2011 Feb; 127 Suppl 3():S64-6. PubMed ID: 21262445
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Placental sFLT1 is associated with complement activation and syncytiotrophoblast damage in preeclampsia.
    Yonekura Collier AR; Zsengeller Z; Pernicone E; Salahuddin S; Khankin EV; Karumanchi SA
    Hypertens Pregnancy; 2019 Aug; 38(3):193-199. PubMed ID: 31291799
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Plasma concentrations of soluble endoglin versus standard evaluation in patients with suspected preeclampsia.
    Rana S; Cerdeira AS; Wenger J; Salahuddin S; Lim KH; Ralston SJ; Thadhani RI; Karumanchi SA
    PLoS One; 2012; 7(10):e48259. PubMed ID: 23110221
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prenatal Low-Dose Aspirin Use Associated with Reduced Incidence of Postpartum Hypertension among Women with Preeclampsia.
    Christenson E; Stout MJ; Williams D; Verma AK; Davila-Roman VG; Lindley KJ
    Am J Perinatol; 2023 Mar; 40(4):394-399. PubMed ID: 33940641
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.